Lucas, C., Vogels, C. B. F., Yildirim, I., Rothman, J. E., Lu, P., Monteiro, V., Gelhausen, J. R., Campbell, M., Silva, J., Tabachikova, A., Peña-Hernandez, M. A., Muenker, M. C., Breban, M. I., Fauver, J. R., Mohanty, S., Huang, J., Shaw, A. C., Ko, A. I., Omer, S. B., … Iwasaki, A. (2021). Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature, 1–9. https://doi.org/10.1038/s41586-021-04085-y

Sadoff, J., Gars, M. L., Cardenas, V., Shukarev, G., Vaissiere, N., Heerwegh, D., Truyers, C., Groot, A. M. de, Scheper, G., Hendriks, J., Ruiz-Guinazu, J., Struyf, F., Hoof, J. V., Douoguih, M., & Schuitemaker, H. (2021). Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting (p. 2021.08.25.21262569). https://doi.org/10.1101/2021.08.25.21262569

Gebre, M. S., Rauch, S., Roth, N., Yu, J., Chandrashekar, A., Mercado, N. B., He, X., Liu, J., McMahan, K., Martinot, A., Martinez, D. R., Giffin, T., Hope, D., Patel, S., Sellers, D., Sanborn, O., Barrett, J., Liu, X., Cole, A. C., … Barouch, D. H. (2021). Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine. Nature, 1–8. https://doi.org/10.1038/s41586-021-04231-6

Collier, A. Y., Brown, C. M., Mcmahan, K., Yu, J., Liu, J., Jacob-Dolan, C., Chandrashekar, A., Tierney, D., Ansel, J. L., Rowe, M., Sellers, D., Ahmad, K., Aguayo, R., Anioke, T., Gardner, S., Siamatu, M., Rivera, L. B., Hacker, M. R., Madoff, L. C., & Barouch, D. H. (2021). Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts (p. 2021.10.18.21265113). https://doi.org/10.1101/2021.10.18.21265113

Gentles, L. E., Kehoe, L., Crawford, K. H. D., Lacombe, K., Dickerson, J., Wolf, C., Yuan, J., Schuler, S., Watson, J. T., Nyanseor, S., Briggs-Hagen, M., Saydah, S., Midgley, C. M., Pringle, K., Chu, H., Bloom, J. D., & Englund, J. A. (2022). Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time (p. 2022.01.14.22269235). medRxiv. https://doi.org/10.1101/2022.01.14.22269235

Taylor, L. (2022). Covid-19: CoronaVac immunity is strongest after boosting with a different vaccine. BMJ, 376, o210. https://doi.org/10.1136/bmj.o210

Richterman, A., Scott, J., & Cevik, M. (2021). Covid-19 vaccines, immunity, and boosters. BMJ, 375, n3105. https://doi.org/10.1136/bmj.n3105

Reuters. (2021, December 20). Moderna says booster produces strong antibody response to Omicron. The Guardian. https://www.theguardian.com/world/2021/dec/20/moderna-booster-strong-antibody-response-omicron-covid-vaccine-variant

Mahase, E. (2021). Covid-19: Do vaccines work against omicron—and other questions answered. BMJ, 375, n3062. https://doi.org/10.1136/bmj.n3062

Mahase, E. (2021). Covid-19: Antibody boost after third dose varies greatly by vaccine, study finds. BMJ, 375, n3011. https://doi.org/10.1136/bmj.n3011

China’s ‘zero Covid’ vs Singapore’s ‘living with it’: Rapid low-cost testing could mean we don’t need to choose | South China Morning Post. (n.d.). Retrieved October 15, 2021, from https://www.scmp.com/comment/opinion/article/3152167/chinas-zero-covid-vs-singapores-living-it-rapid-low-cost-testing

Geddes, L. (2021, September 28). Covid can infect cells in pancreas that make insulin, research shows. The Guardian. https://www.theguardian.com/society/2021/sep/29/covid-can-infect-cells-in-pancreas-that-make-insulin-research-shows

Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A. (2021). Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Science Immunology. https://doi.org/10.1126/sciimmunol.abl4509

Liu, Y., Arase, N., Kishikawa, J., Hirose, M., Li, S., Tada, A., Matsuoka, S., Arakawa, A., Akamatsu, K., Ono, C., Jin, H., Kishida, K., Nakai, W., Kohyama, M., Nakagawa, A., Yamagishi, Y., Nakagami, H., Kumanogoh, A., Matsuura, Y., … Arase, H. (2021). The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines (p. 2021.08.22.457114). https://doi.org/10.1101/2021.08.22.457114

Thushan de Silva on Twitter. (n.d.). Twitter. Retrieved 29 July 2021, from https://twitter.com/Thushan_deSilva/status/1418511974435115011

Tada, Takuya, Hao Zhou, Marie I. Samanovic, Belinda M. Dcosta, Amber Cornelius, Mark J. Mulligan, and Nathaniel R. Landau. “Comparison of Neutralizing Antibody Titers Elicited by MRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants.” BioRxiv, July 19, 2021, 2021.07.19.452771. https://doi.org/10.1101/2021.07.19.452771.

Barouch, Dan H., Kathryn E. Stephenson, Jerald Sadoff, Jingyou Yu, Aiquan Chang, Makda Gebre, Katherine McMahan, et al. “Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.” New England Journal of Medicine 0, no. 0 (July 14, 2021): null. https://doi.org/10.1056/NEJMc2108829.

Griffin, S. (2021). Covid-19: China’s CoronaVac vaccine offers 83.5% protection against symptomatic infection, interim analysis finds. BMJ, 374, n1755. https://doi.org/10.1136/bmj.n1755

magazine, H. L., Nature. (n.d.). Delaying a COVID Vaccine’s Second Dose Boosts Immune Response in the Elderly. Scientific American. Retrieved 30 May 2021, from https://www.scientificamerican.com/article/delaying-a-covid-vaccine-rsquo-s-second-dose-boosts-immune-response-in-the-elderly/

Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A. (2021). Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. BioRxiv, 2021.05.19.444825. https://doi.org/10.1101/2021.05.19.444825

Edara, Venkata Viswanadh, William H. Hudson, Xuping Xie, Rafi Ahmed, and Mehul S. Suthar. “Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination.” JAMA, March 19, 2021. https://doi.org/10.1001/jama.2021.4388.

Mandavilli, A. (2021, January 28). Some Covid Survivors Have Antibodies That Attack the Body, not Virus. The New York Times. https://www.nytimes.com/2020/10/27/health/covid-antibodies-autoimmunity.html

Nature Editorial. (2020, October 23). The race to make COVID antibody therapies cheaper and more potent. Nature. https://www.nature.com/articles/d41586-020-02965-3?utm_source=twt_nnc&utm_medium=social&utm_campaign=naturenews&sf239165668=1&error=cookies_not_supported&code=2b2dd7c6-d01f-4057-8389-3be656a7ba58

ReconfigBehSci. (2020, November 21). RT @DrEricDing: Good question for immunologists like @michaelmina_lab @VirusesImmunity and @PeterHotez. Https://t.co/Rs1zaUPznm [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1334804615842439170

Scientists study whether immune response wards off or worsens Covid. (2020, October 4). The Guardian. http://www.theguardian.com/science/2020/oct/04/scientists-study-whether-immune-response-wards-off-or-worsens-covid

Commissioner, O. of the. (2020, September 23). Coronavirus (COVID-19) Update: FDA Authorizes First Point-of-Care Antibody Test for COVID-19. FDA; FDA. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-point-care-antibody-test-covid-19

Beware comforting lies about a “herd immunity” Covid-19 strategy. Here’s why it’s dangerous – Professor Devi Sridhar. (n.d.). Retrieved September 25, 2020, from https://www.scotsman.com/news/opinion/columnists/covid-19-herd-immunity-strategy-flawed-until-we-have-coronavirus-vaccine-professor-devi-sridhar-2981017

Bangaru, S., Ozorowski, G., Turner, H. L., Antanasijevic, A., Huang, D., Wang, X., Torres, J. L., Diedrich, J. K., Tian, J.-H., Portnoff, A. D., Patel, N., Massare, M. J., Yates, J. R., Nemazee, D., Paulson, J. C., Glenn, G., Smith, G., & Ward, A. B. (2020). Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. BioRxiv, 2020.08.06.234674. https://doi.org/10.1101/2020.08.06.234674

Ledford, H. (2020). What the immune response to COVID-19 says about the prospects for a vaccine. Nature. https://doi.org/10.1038/d41586-020-02400-7

SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months | medRxiv. (n.d.). Retrieved 1 August 2020, from https://www.medrxiv.org/content/10.1101/2020.07.14.20151126v1.article-metrics

Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., Su, K., Zhang, F., Gong, J., Wu, B., Liu, X.-M., Li, J.-J., Qiu, J.-F., Chen, J., & Huang, A.-L. (2020). Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature Medicine, 1–5. https://doi.org/10.1038/s41591-020-0965-6

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., Hagglof, T., Oliveira, T. Y., Viant, C., Hurley, A., Hoffmann, H.-H., Millard, K. G., Kost, R. G., Cipolla, M., Gordon, K., … Nussenzweig, M. C. (2020). Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals [Preprint]. Immunology. https://doi.org/10.1101/2020.05.13.092619

Crotty, S. (2020, May 14). "Our new paper rapidly studied T cell + antibody immune responses in average COVID-19 cases. This is good news in multiple ways, including coronavirus vaccines. @ljiresearch cell.com/cell/fulltext/..." Twitter. https://twitter.com/profshanecrotty/status/1261052353773363200

WHO “Immunity passports” in the context of COVID-19. (2020 April 27). https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19